JP2011500592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500592A5 JP2011500592A5 JP2010529076A JP2010529076A JP2011500592A5 JP 2011500592 A5 JP2011500592 A5 JP 2011500592A5 JP 2010529076 A JP2010529076 A JP 2010529076A JP 2010529076 A JP2010529076 A JP 2010529076A JP 2011500592 A5 JP2011500592 A5 JP 2011500592A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- vaccine
- cell type
- cell
- population
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701022 Cytomegalovirus Species 0.000 claims 34
- 229960005486 vaccine Drugs 0.000 claims 18
- 210000004027 cell Anatomy 0.000 claims 16
- 238000000034 method Methods 0.000 claims 10
- 210000002919 epithelial cell Anatomy 0.000 claims 6
- 238000004113 cell culture Methods 0.000 claims 5
- 210000002950 fibroblast Anatomy 0.000 claims 5
- 230000001143 conditioned effect Effects 0.000 claims 4
- 210000002845 virion Anatomy 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 2
- 230000036755 cellular response Effects 0.000 claims 2
- 210000004748 cultured cell Anatomy 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 1
- 230000007910 cell fusion Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims 1
- 210000002536 stromal cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99842607P | 2007-10-10 | 2007-10-10 | |
| US60/998,426 | 2007-10-10 | ||
| PCT/US2008/079494 WO2009049138A1 (en) | 2007-10-10 | 2008-10-10 | Cytomegalovirus vaccines and methods of production |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500592A JP2011500592A (ja) | 2011-01-06 |
| JP2011500592A5 true JP2011500592A5 (enExample) | 2011-10-20 |
| JP5409638B2 JP5409638B2 (ja) | 2014-02-05 |
Family
ID=40549581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529076A Expired - Fee Related JP5409638B2 (ja) | 2007-10-10 | 2008-10-10 | サイトメガロウイルスワクチンおよび製造方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9439960B2 (enExample) |
| EP (1) | EP2200645B1 (enExample) |
| JP (1) | JP5409638B2 (enExample) |
| KR (1) | KR20100084627A (enExample) |
| CN (1) | CN101820906B (enExample) |
| AU (1) | AU2008310713B2 (enExample) |
| BR (1) | BRPI0818656A2 (enExample) |
| CA (1) | CA2701727C (enExample) |
| IL (1) | IL204850A0 (enExample) |
| MX (1) | MX2010003713A (enExample) |
| NZ (1) | NZ584459A (enExample) |
| RU (1) | RU2491340C2 (enExample) |
| SG (1) | SG185291A1 (enExample) |
| WO (1) | WO2009049138A1 (enExample) |
| ZA (1) | ZA201002216B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
| US8580276B2 (en) | 2009-06-05 | 2013-11-12 | City Of Hope | Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof |
| TWI570240B (zh) | 2011-09-09 | 2017-02-11 | 默沙東公司 | 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ |
| EP2831285B1 (en) * | 2012-03-27 | 2019-10-30 | Variation Biotechnologies Inc. | Methods for detection of anti-cytomegalovirus neutralizing antibodies |
| MX378747B (es) | 2012-07-06 | 2025-03-10 | Glaxosmithkline Biologicals S A Star | Complejos de proteínas de citomegalovirus. |
| AU2013293570B2 (en) | 2012-07-27 | 2019-05-23 | City Of Hope | An MVA vaccine for delivery of a UL128 complex and preventing CMV infection |
| US9395369B2 (en) | 2012-10-19 | 2016-07-19 | Regents Of The University Of Minnesota | Guinea pig cytomegalovirus (CIDMTR strain) |
| CN103937871B (zh) * | 2013-01-23 | 2019-07-23 | 上海市东方医院 | Srrp35基因和表达产物在癌症诊断与治疗中的应用 |
| US20160289303A1 (en) * | 2013-11-15 | 2016-10-06 | President And Fellows Of Harvard College | Methods and compositions for the treatment of hcmv |
| US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| EP3601543A4 (en) * | 2017-03-30 | 2021-01-27 | Merck Sharp & Dohme Corp. | ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS |
| CA3060019A1 (en) * | 2017-04-19 | 2018-10-25 | Glaxosmithkline Biologicals Sa | Modified cytomegalovirus proteins and stabilized complexes |
| WO2019089410A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Stable formulations of cytomegalovirus |
| US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
| TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3959466A (en) | 1974-04-15 | 1976-05-25 | The Wistar Institute | Highly attenuated cytomegalovirus vaccine and production thereof |
| US4058598A (en) | 1974-10-18 | 1977-11-15 | Harold Stern | Cytomegalovirus attenuation method and vaccine |
| US6471965B1 (en) | 1994-07-27 | 2002-10-29 | Bio-Virus Research Incorporated | Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque |
| DE10144906B4 (de) * | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| WO2005012545A2 (en) | 2003-07-25 | 2005-02-10 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors |
| CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
| US9439960B2 (en) | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
-
2008
- 2008-10-01 US US12/681,504 patent/US9439960B2/en active Active
- 2008-10-10 NZ NZ584459A patent/NZ584459A/en not_active IP Right Cessation
- 2008-10-10 JP JP2010529076A patent/JP5409638B2/ja not_active Expired - Fee Related
- 2008-10-10 WO PCT/US2008/079494 patent/WO2009049138A1/en not_active Ceased
- 2008-10-10 CN CN200880111084.9A patent/CN101820906B/zh not_active Expired - Fee Related
- 2008-10-10 SG SG2012075594A patent/SG185291A1/en unknown
- 2008-10-10 MX MX2010003713A patent/MX2010003713A/es active IP Right Grant
- 2008-10-10 EP EP08836810.5A patent/EP2200645B1/en active Active
- 2008-10-10 CA CA2701727A patent/CA2701727C/en active Active
- 2008-10-10 KR KR1020107008187A patent/KR20100084627A/ko not_active Withdrawn
- 2008-10-10 BR BRPI0818656-1A patent/BRPI0818656A2/pt not_active IP Right Cessation
- 2008-10-10 AU AU2008310713A patent/AU2008310713B2/en not_active Ceased
- 2008-10-10 RU RU2010117741/10A patent/RU2491340C2/ru not_active IP Right Cessation
-
2010
- 2010-03-29 ZA ZA2010/02216A patent/ZA201002216B/en unknown
- 2010-04-06 IL IL204850A patent/IL204850A0/en unknown
-
2016
- 2016-07-29 US US15/223,980 patent/US10300130B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011500592A5 (enExample) | ||
| CN108486108B (zh) | 一种敲除人hmgb1基因的细胞株及其应用 | |
| RU2010117741A (ru) | Вакцина против цитомегаловируса и способ ее получения | |
| Chi et al. | Temperature effect on nervous necrosis virus infection in grouper cell line and in grouper larvae | |
| JP2013533745A5 (enExample) | ||
| US20220389391A1 (en) | F-genotype mumps virus attenuated strain and construction method therefor and application thereof | |
| CN102628053B (zh) | 重组鸡马立克氏病病毒sc9-1株和sc9-2株的构建和应用 | |
| JP2010506586A5 (enExample) | ||
| CN105316356B (zh) | 微藻多基因共表达载体及多基因共表达微藻 | |
| CN102210861A (zh) | 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗 | |
| CN102911883A (zh) | 一种酵母麦角固醇高产菌株及其选育方法与应用 | |
| RU2494106C2 (ru) | Гены, кодирующие главный капсидный белок l1 вируса папилломы человека, и их применение | |
| CN114990075B (zh) | 一株可适用于人用疫苗细胞基质培养的柯萨奇病毒a组10型疫苗株及其应用 | |
| CN104894054B (zh) | 一种猴胚胎肾上皮细胞Marc‑145悬浮适应株及其在培养蓝耳病病毒、生产蓝耳病毒疫苗中的应用 | |
| CN110423782A (zh) | 一株Marc-145稳定细胞株的构建及应用 | |
| CN105400745A (zh) | 一种猪繁殖与呼吸综合征病毒基因工程毒株及其灭活疫苗和疫苗制备方法 | |
| CN113583980A (zh) | 一种猪繁殖与呼吸综合征突变病毒及其构建方法与应用 | |
| CN102911920A (zh) | Ⅱ型登革病毒kmb17细胞适应株及其制备方法 | |
| CN103992962A (zh) | 变异链球菌rnc基因突变株及其应用 | |
| Marcelino et al. | Characterization of Ehrlichia ruminantium replication and release kinetics in endothelial cell cultures | |
| CN112661819A (zh) | 新型冠状病毒rbd的重组病毒样颗粒及其构建方法 | |
| CN104087549B (zh) | 高产杆状病毒的昆虫细胞系及其应用 | |
| CN113151171B (zh) | 猪肺泡巨噬细胞健康细胞系及构建方法与应用 | |
| CN110643520A (zh) | 高产南极紫红色素的南极真菌Geomyces sp.突变株及其应用 | |
| CN118460584A (zh) | 基于CRISPR-Cas9系统的营养缺陷型乳酸菌基因编辑系统及应用 |